

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Sagard Capital Partners, L.P.</u> (Last) (First) (Middle) 280 PARK AVENUE, 3RD FLOOR WEST (Street) NEW YORK NY 10017 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Jaguar Health, Inc. [JAGX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/14/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Convertible Participating Preferred Stock	\$2.775	03/14/2019		H		5,524,926		(2)(3)(4)(5)	(2)(3)(4)(5)	Voting Common Stock	3,314,956	(6)	0	1 ⁽⁷⁾	See Footnote ⁽⁷⁾
Series A Convertible Participating Preferred Stock	\$0.2775 ⁽¹⁾	03/14/2019		P		5,524,926		(2)(3)(4)(5)	(2)(3)(4)(5)	Voting Common Stock	33,149,556	(6)	5,524,926	1 ⁽⁷⁾	See Footnote ⁽⁷⁾

1. Name and Address of Reporting Person*
Sagard Capital Partners, L.P.
 (Last) (First) (Middle)
 280 PARK AVENUE, 3RD FLOOR WEST
 (Street)
 NEW YORK NY 10017
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Sagard Capital Partners GP, Inc.
 (Last) (First) (Middle)
 280 PARK AVENUE, 3RD FLOOR WEST
 (Street)
 NEW YORK NY 10017
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Sagard Capital Partners Management Corp
 (Last) (First) (Middle)
 280 PARK AVENUE, 3RD FLOOR WEST
 (Street)
 NEW YORK NY 10017
 (City) (State) (Zip)

Explanation of Responses:

1. Each share of Series A Preferred Stock ("Preferred Stock") is now convertible into six shares of Voting Common Stock at an effective conversion price of \$0.2775 per share (based on an original price per share of Preferred

